Schedule 13D ownership disclosure

CLEARSIDE BIOMEDICAL INC

Common Stock, $0.001 Par Value · CUSIP: 185063104

Event date: 2024-09-13

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Hatteras Venture Advisors IV SBIC, LLCReported CIK 0001675236

    Shares: 0.00 · Class: 0%

  • Hatteras Venture Partners IV SBIC, LP

    Shares: 0.00 · Class: 0%

  • Hatteras Venture Advisors IV, LLC

    Shares: 0.00 · Class: 0%

  • Hatteras Venture Partners IV, LP

    Shares: 0.00 · Class: 0%

  • Hatteras NC Fund, LP

    Shares: 0.00 · Class: 0%

  • John C. Crumpler

    Shares: 125,793.00 · Class: 0.2%

  • Robert A. Ingram

    Shares: 130,881.00 · Class: 0.2%

  • Kenneth B. Lee

    Shares: 86,324.00 · Class: 0.1%

  • Clay B. Thorp

    Shares: 313,641.00 · Class: 0.4%

  • Douglas Reed

    Shares: 127,011.00 · Class: 0.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-25-016122
Form type
SCHEDULE 13D/A
Filer
Clearside Biomedical, Inc.
CIK
CIK 1539029
Filed
Feb 21, 2025
Reporting period
Sep 13, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub